The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter.
https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png00shanel_nelsonhttps://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.pngshanel_nelson2021-09-06 20:36:142021-09-06 20:36:14House Committees Demand F.D.A. Records on Alzheimer’s Drug Approval
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.